PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of patsIssue Featuring ArticlePublisher's Version of ArticleSubmissionsAmerican Thoracic SocietyAmerican Thoracic SocietyProceedings of the American Thoracic Society
 
Proc Am Thorac Soc. 2005 October; 2(3): 214–220.
PMCID: PMC2713319

Apoptosis and Epithelial Injury in the Lungs

Abstract

Epithelial injury is a critical event in the development of acute lung injury, but the mechanisms that cause death of the alveolar epithelium are not completely understood. Epithelial death occurs by necrosis and apoptosis; more information is needed about the balance between these two types of cell death in the lungs. Direct epithelial necrosis probably occurs in response to bacterial exotoxins and overdistension of alveolar units by mechanical ventilation. Apoptosis is a regulated form of cell death that is mediated by membrane death receptors and direct mitochondrial injury. Apoptosis pathways are activated in the lungs of patients with acute lung injury, in part by activation of the membrane Fas death receptor by soluble Fas ligand (sFasL), which accumulates in biologically active form at the onset of lung injury. Accumulating evidence in humans and experimental models links sFasL and Fas pathway with lung epithelial injury and fibrosis. New strategies to inhibit Fas-mediated epithelial apoptosis need to be developed in order to develop new ways to preserve epithelial function in patients who develop acute lung injury.

Keywords: apoptosis, epithelial, lung injury

The acute respiratory distress syndrome (ARDS) causes approximately 80,000 deaths each year in the United States, and the mortality in unselected patients continues to exceed 40%. The ARDSnet studies of mechanical ventilation strategies in patients with ARDS established that a simple mechanical intervention, applying less stretch to the lungs, is consistently associated with lower mortality (1, 2). Yet overall mortality remains unacceptably high, and an improved understanding of the pathophysiology of acute lung injury (ALI) in humans is needed in order to develop treatments that will be additive or synergistic with mechanical ventilation strategies in reducing overall mortality. Soon after the initial description of ARDS in humans, it was recognized that alveolar inflammation was an important feature of ARDS (3), and many laboratories investigated the inflammatory events in the lungs of patients, and the role of inflammation in models of experimental lung injury (4). More recently, interest has focused on other mechanisms that cause alveolar injury, either instead of or in addition to inflammation. Apoptosis is a form of programmed cell death that is essential to tissue development and repair, and it also appears to be important in the pathophysiology of some diseases (5, 6). This brief review will summarize some of the potential links between apoptosis and alveolar injury in humans and experimental models of ALI.

ALVEOLAR EPITHELIAL INJURY IN PATIENTS WITH ALI

Epithelial injury in the lungs is one of the hallmarks of ALI in humans. The classical studies of Bachofen and Weibel identified ultrastructural injury to alveolar Type I epithelial cells in patients who had died of ARDS (7, 8). Although injury to the lung microvasculature was also detected, the vascular lesions were not as prominent as the epithelial destruction. Autopsy studies do not clarify how early epithelial injury occurs, or how it progresses in patients after onset of lung injury. One of the characteristics of acute inflammation is that endothelial permeability increases rapidly. In the lungs this results in the movement of plasma equivalents into the interstitial space, and this extravascular fluid moves into lymphatic spaces along bronchovascular bundles. If microvascular or interstitial pressures are high, alveolar flooding can result. The increase in extravascular fluid alters ventilation/perfusion relationships, and the resulting hypoxemia can be severe. Yet if endothelial permeability is the sole change in the lungs, extravascular fluid is eventually cleared from the interstitial and alveolar spaces, and the lungs heal without fibrosis because no major structural damage has occurred. In contrast, when the alveolar epithelium is damaged the change in epithelial permeability leads to major alveolar flooding with high-molecular-weight proteins, with prolonged changes in gas exchange and a much higher likelihood of disordered repair.

Endothelial permeability changes rapidly in response to local and systemic proinflammatory stimuli, and changes in endothelial permeability are rapidly reversible in the absence of severe endothelial damage. In contrast, the lung alveolar epithelium is an extremely tight barrier that restricts the movement of proteins and liquid from the interstitium into the alveolar spaces. In addition, the lung epithelium contains specialized transport systems that pump sodium chloride from the alveolar spaces into the interstitium (9). Protein is transported more slowly across the alveolar epithelium than electrolytes and water. As a result, when epithelial function is normal and plasma equivalents reach the alveolar spaces, the protein concentration in alveolar fluid rises with time, as water and electrolytes are reabsorbed faster than protein. Clinical studies show that patients in whom the alveolar protein concentration rises over a period of hours after the clinical onset of ALI have a better prognosis than those in whom the protein concentration remains constant or falls, consistent with the interpretation that impaired alveolar epithelial function in the lungs is a marker of poor outcome in humans (10, 11).

MECHANISMS OF ALVEOLAR EPITHELIAL DEATH

Cell death occurs by two general mechanisms, necrosis and apoptosis, and we have an incomplete understanding about the mechanisms that determine which of these two processes occurs. Necrosis is likely when tissue becomes ischemic and tissue oxygen tension falls abruptly. This is probably less common in the lungs than in other tissues because of the dual pulmonary circulations and the ventilated alveolar spaces. Some bacterial exotoxins cause direct lysis of epithelial cells, including the type III toxins produced by Pseudomonas species, and exotoxins released by Escherichia coli and Staphylococcus aureus (1214). Mechanical forces created by shear stress or overdistension may also cause direct disruption of epithelial membranes, particularly in injured lungs in which heterogeneous alveolar flooding leads to marked heterogeneity in regional compliance (15, 16).

Apoptosis is a form of regulated cell death in which activation of specific intracellular serine rich proteases (caspases) leads to DNA cleavage and cell death. Apoptosis is an essential feature of development, and provides a mechanism for tissue remodeling in specific regions such as the interdigital spaces of fingers and toes. In general, apoptosis occurs without the release of intracellular products, whereas necrosis is associated with cellular swelling, membrane rupture, and the escape of intracellular products into the local environment. Apoptosis is a Greek word meaning “falling away,” like leaves falling from trees in the autumn. Apoptosis occurs in response to activation of specific cell membrane receptors, termed “death receptors,” as well as in response to the release of mitochondrial products such as cytochrome C (17) (Figure 1). The death receptor family includes the TNF receptors I and II, and the Fas receptor (CD95), which is activated either by Fas ligand (FasL) on the surface of cytotoxic lymphocytes, or by a soluble form of FasL (sFasL), which can be cleaved from cell membranes by the action of specific serine proteinases such as matrix metalloproteinases 7 and 3 (MMP-7, MMP-3) (18, 19). Soluble FasL is also released from activated blood monocytes, but it does not appear to be released from activated alveolar macrophages (20). Activation of the mitochondrial and the receptor pathways of apoptosis have been reported in the lungs, but this review focuses primarily on the Fas receptor–mediated apoptosis pathway.

Figure 1.
Cellular pathways that mediate apoptosis. A family of death receptors can initiate apoptosis, and their relative importance depends on the cell type. Two major pathways are shown here: the Fas receptor pathway and the receptor-independent mitochondrial ...

When membrane Fas is clustered by FasL, specialized docking proteins (including Fas-associated death domain [FADD]) aggregate around the intracellular tails of clustered Fas molecules. This death-initiating complex (DISC) recruits procaspase 8 molecules, which undergo activation by autocatalytic cleavage, resulting in the activation of a cascade of downstream intracellular caspases. This eventually causes activation of endonucleases, with cleavage of nuclear DNA and cell death. The DNA cleavage is detectable as a “laddering” effect of DNA fragments of different molecular weights when cellular DNA is analyzed by electrophoresis in agarose gels. DNA cleavage is also detectable by assays which identify nucleotide cleavage sites using a terminal deoxynucleotide transferase enzyme (TUNEL assay) (21, 22). Activated caspase 3, a distal enzyme in the caspase cascade, can be detected in cells and tissues using antibodies specific for the cleaved (activated) form of caspase 3. In addition to the Fas receptor–mediated pathway, mitochondrial damage caused by ultraviolet light and other toxins initiates apoptosis via the release of cytochrome C, which binds to Apaf-1 and activates caspase 9, and subsequently caspase 3, followed by DNA fragmentation and apoptotic cell death (Figure 1).

Cellular apoptosis is tightly regulated by several different inhibitory proteins, so that cell death can be controlled at the appropriate times. A family of proteins, inhibitors of apoptosis (IAP), directly bind and inhibit caspases 3, 6, 7, and 9 (23). The mitochondrial pathway is inhibited by the Bcl-2 family of proteins, which block activation of caspases by cytochrome C (24, 25). An additional family, FLICE/caspase-8 inhibitory proteins (FLIP), includes mammalian and viral proteins, which interfere directly with the activation of caspase-8 recruited to the Fas/FADD membrane complex (17, 26, 27). Viral FLIPs provide a unique mechanism to prolong the lives of infected cells by blocking apoptosis pathways (28).

Although the membrane receptor pathway and the mitochondrial pathways for apoptosis differ initially, the terminal events leading to DNA damage are similar, and available assays cannot differentiate the initial stimuli which cause apoptosis. Apoptosis leads to the loss of polarization of the cell membrane, which is detectable as an increase in the expression of phosphatidylserine on the outer leaflet of the lipid bilayer using the binding of the fluorescent indicator annexin V (29, 30). Apoptotic leukocytes are recognized and ingested by tissue macrophages via specific surface receptors on the cell membrane (31). Because this process is extremely rapid, the number of visible apoptotic leukocytes at sites of tissue inflammation is usually low, and probably underestimates the extent to which apoptosis is occurring (32).

One of the consequences of apoptosis is loss of cellular attachment to the underlying basement membrane. This could result in the exposure of the underlying alveolar epithelial basement membrane to inflammatory products in the alveolar spaces, such as oxidants, proteinases, and other elements of the inflammatory milieu. Destruction of the alveolar walls and activation of fibroblast proliferation and collagen production, which is known to occur at the onset of ALI in humans, could lead to fibrosis during the repair process (33). Identifying the mechanisms that link apoptosis with acute and chronic fibrosis in the lungs is an important objective of ongoing research.

APOPTOSIS IN ALI

The importance of apoptosis in the resolution of inflammation led us to investigate the number of apoptotic PMN recovered from the lungs of patients at the onset and during the course of ALI. Apoptotic PMN are recognizable using hematoxylin eosin staining by their characteristic pattern of nuclear condensation. Examination of bronchoalveolar lavage cells prepared by cytocentrifugation revealed few apoptotic PMN, as less than 10% of recovered PMN had morphologic features of apoptosis (34). Studies of freshly isolated PMN showed that the bronchoalveolar lavage fluid from patients with lung injury contained factor(s) that delayed PMN apoptosis, principally granulocyte-macrophage colony stimulating factor (GM-CSF) (34). This cytokine provides a mechanism for prolonging PMN survival in tissue and its role is not limited to inflammation in the lungs. Interestingly, electron microscopic analysis of alveolar macrophages in the same specimens showed that more than 30% of the macrophages contained particles suggesting PMN cellular debris such as myeloperoxidase granules. This is consistent with the view that apoptotic PMN are taken up rapidly by activated lung macrophages. Thus two processes are likely to be occurring simultaneously: PMN apoptosis is delayed in the airspaces, and apoptotic PMN are taken up very rapidly by activated macrophages.

Because bronchoalveolar lavage fluid contained factors that modified PMN apoptosis, we also investigated the effect of lung lavage fluid on epithelial cell apoptosis and the results were strikingly different. Earlier studies of human lung tissue had shown that Fas is present on proliferating Type II pneumocytes, as well as airway epithelial cells, and Fas-mediated apoptosis had been proposed as a mechanism to clear proliferating Type II pneumocytes during lung repair (3538). We found that the bronchoalveolar lavage fluid of patients with ARDS induced apoptosis in airway epithelial cells derived from the distal lung airways of normal human lungs (39). These distal lung epithelial cells contain lamellar bodies and surfactant protein A (SP-A), but they are not true Type II pneumocytes because they are obtained by microdissection of 1- to 2-mm airways of excised human lungs. The bronchoalveolar lavage fluid was found to contain sFasL (Figure 2) before and after the onset of ARDS, but the sFasL was biologically active only at the onset of ARDS (39). The decoy receptor, DcR3 (40), was also detectable in the lung lavage fluid of these same patients, but the ratio of DcR3 to sFasL provided an incomplete explanation for the bioactivity of the sFasL at the onset of ARDS.

Figure 2.
Soluble Fas ligand concentrations (sFasL) measured by specific immunoassay in the bronchoalveolar lavage fluid of normal volunteers (Normal), patients at risk for ARDS because of either clinical sepsis or trauma (At risk), and patients with established ...

Albertine and coworkers also found sFasL in the lung edema fluids of patients with ALI, and confirmed that soluble Fas is detectable by immunoassay (41). Histologic studies of the lungs of different patients with ALI showed increased expression of Fas on the alveolar epithelium of patients who died, as compared with patients who died of other causes. The studies by Matute-Bello and colleagues and by Albertine and coworkers suggested that activation of the Fas pathway is an important mechanism of alveolar epithelial injury in the lungs of patients with ALI, in addition to direct epithelial necrosis caused by mechanical factors, local ischemia, or bacterial products in the airspaces (39, 40).

Clearly, other pathways in addition to the Fas receptor pathway also have the potential to induce epithelial apoptosis in ALI. Importantly, hyperoxia and hypoxia each can induce apoptosis of pulmonary epithelial cells in experimental systems, and both are relevant in patients with ALI who are ventilated with a high FiO2, yet at the same time may have regions of tissue hypoxia where alveolar collapse has occurred. Buccellato and associates found that hyperoxia induced apoptosis of primary rat alveolar epithelial cells in vitro by activating the pro-apoptotic protein “Bax” at the mitochondrial membrane (42). This leads to the release of mitochondrial cytochrome C, which activates caspase 9, leading to cellular apoptosis. In contrast, Krick and coworkers found that exposure of rat type II cells to graded hypoxia suppressed proliferation and caused apoptosis by a mechanism that involves activation of hypoxia inducible factor (HIF-1α), and the hypoxia response element (HRE) in nuclear DNA (43). These authors speculated that targeting the HIF-1α/HRE pathway, perhaps with a low-molecular-weight inhibitor, might be an additional strategy to reduce epithelial apoptosis in ALI.

APOPTOSIS IN HUMAN AIRWAY EPITHELIAL CELLS

The consequences of Fas activation differ at different locations along the airway and alveolar epithelium. We compared the responses of proximal and distal nontransformed human airway epithelial cells and found that proximal airway epithelial cells are insensitive to Fas-induced apoptosis, whereas distal epithelial cells are much more sensitive (44). Rabbit and mouse alveolar type II cells are sensitive to Fas activation either by human sFasL (in rabbit pneumocytes) or a specific monoclonal antibody which clusters membrane Fas (in murine pneumocytes) (45). The mechanism for the differential sensitivity of proximal and distal pneumocytes to sFasL remains unclear, as both types of cells express membrane Fas and contain similar patterns of steady-state mRNAs for the Fas pathway intermediate proteins. These studies raise the possibility that there is a gradient of Fas sensitivity in the lungs, with the proximal airways relatively insensitive to sFasL in airspace fluids and increasing sensitivity moving distally in the airways and into the alveolar space.

APOPTOSIS IN MODELS OF ACUTE AND CHRONIC LUNG INJURY

The importance of apoptosis pathways in acute and chronic lung injury has been investigated in a number of different animal models. When recombinant human sFasL was instilled into the lungs of rabbits, localized alveolar hemorrhage was observed. This was not present in the contralateral lungs of the same animals that had been treated with human sFasL together with an inhibitory immunoglobulin construct containing a human Fas peptide sequence in the variable region. Interestingly, the sFasL activated inflammatory pathways in the lungs, as reflected by immunohistochemical evidence of IL-8 expression in alveolar macrophages where sFasL had deposited in the airspaces. Activation of Fas in the lungs of mice using a single intratracheal dose of the activating monoclonal antibody, Jo2, causes acute inflammation and evidence of apoptosis in alveolar walls within 24 h after instillation of the Jo2 antibody (46). Recently, Wang and associates showed that the caspase-8/Bid pathway is important in signaling associated with hyperoxic lung injury and cell death in vivo and in vitro (47). In addition to epithelial apoptosis, endothelial cell apoptosis also been found to occur in the lungs in a murine model of hemorrhagic shock (48).

Fas activation has also been linked to chronic lung injury, because repeated exposure to daily aerosols of the Jo-2 antibody for 14 d caused acute inflammation and delayed evidence of collagen accumulation, consistent with a fibrotic response in the lungs (49). Mice lacking the Fas receptor (lpr mice) had a blunted response to intrapulmonary bleomycin, with reduced hydroxyproline accumulation following bleomycin exposure, suggesting a role for the Fas pathway in pulmonary fibrosis due to other agents (50). Stimulation of Fas in the lungs of mice is associated with delayed expression of mRNA for TGF-βs, and TGF-β was found to potentiate the effects of sFasL in human lung epithelial cells in vitro (51). Because a relatively small increase in the rate of epithelial cell apoptosis can result in considerable cell loss over time, a relatively minor upregulation of epithelial apoptosis, particularly of alveolar Type II cells, could account for the excessive epithelial loss and failure of reepithelialization that is characteristic of pulmonary fibrosis. Epithelial apoptosis is found in the lungs of patients with idiopathic pulmonary fibrosis and in the lungs of mice and rats with bleomycin-induced pulmonary fibrosis (5255). Interestingly, fibroblast activation in acute or chronic lung injury may compound epithelial cell apoptosis, as Uhal and coworkers and Wang and colleagues found that fibroblasts from fibrotic lungs induced apoptosis of alveolar epithelial cells in vitro, and that angiotensin peptides appeared to have a causal role in this process (56, 57).

The release of sFasL in the systemic circulation may connect lung injury with distant organ injury. Studies of mechanically ventilated rabbits showed more apoptosis in the renal tubular epithelial cells than in the lung epithelium, and serum from patients with ALI contained detectable sFasL in concentrations that were directly related to the serum creatinine concentration (58). Soluble FasL could not be measured in the rabbit serum because of the lack of an immunologic assay at the time of the study. Similarly, a caspase inhibitor (ZVAD) protected mice from lung inflammation and death after systemic treatment with LPS, suggesting that apoptosis pathways are involved in LPS-dependent inflammatory events in mice (59). More information is needed about the relationships between lung injury, activation of Fas pathways in the lungs and systemic circulation, and apoptosis in distant organs.

Recent evidence indicates that phagocytic clearance of apoptotic cells primes the immune system against autoantigens, and plays an immunoregulatory role (60). Apoptotic cells have been increasingly recognized as targets of autoantibodies that arise in a broad spectrum of autoimmune diseases. The evidence that apoptotic cells are targeted by autoantibodies was provided by studies showing that autoantibodies from humans and mice with systemic lupus erythematosus (SLE) recognize autoantigens that are prominently clustered in the surface blebs of apoptotic cells (61, 62). In addition, immunization of mice with syngeneic apoptotic cells has been reported to induce a humoral immune response to apoptotic cells (63). Thus, cells undergoing apoptosis provide “proinflammatory” signals, mediating autoimmune and inflammatory responses. This could be relevant for the pathogenesis of collagen-related lung diseases, which have high frequencies of associated lung fibrosis.

APOPTOSIS AND INFECTION

A report by Grassme and coworkers indicating that Pseudomonas organisms disseminated more readily from the lungs of mice deficient in Fas ligand suggested a role for the Fas system in host defenses in the lungs, even though Pseudomonas caused apoptosis in the lungs of normal mice (64). The implication was that strategies to block Fas-dependent responses in the lungs might increase host susceptibility to bacterial infection. In this study, the bacteria were delivered by intratracheal inoculation, and the bacterial inoculum was relatively high. We used a bacterial aerosol model to compare bacterial clearance from the lungs of normal and Fas-deficient mice (lpr mice). The clearance of S. aureus, Streptococcus pneumoniae, and E. coli was similar in the normal and the lpr mice, and there were no major differences in neutrophil recruitment to the lungs (65). However, the normal mice had more severe tissue injury than the lpr mice in response to E. coli, with evidence of alveolar wall thickening, vascular congestion, and neutrophilic inflammation. Thus, at the bacterial inocula that are achieved by the aerosol method (about 106 cfu/lung), Fas dependent signaling is not critical for the effective clearance of these gram-positive and gram-negative bacteria, but the Fas system appears to have a role in tissue injury caused by gram-negative bacteria.

There is an important degree of cross-talk between Fas-dependent apoptosis pathways and proinflammatory pathways, despite the fact that apoptosis was originally thought to be a relatively “silent” mode of cell death. In human airway epithelial cells, activation of Fas with an activating monoclonal antibody (CH-11) has been reported to cause NF-κB activation and IL-8 secretion (66). In human monocyte–derived macrophages, Fas stimulation does not lead to apoptosis, but rather to NF-κB activation and the production of TNF-α, IL-8, and other proinflammatory cytokines (67). Earlier, we had found that instillation of recombinant human sFasL into the lungs of rabbits caused IL-8 expression in lung macrophages in vivo, but the mechanism for this was unclear at the time (45). Mice lacking Fas have reduced intrapulmonary inflammatory responses to LPS in vivo, showing that the interaction between the Fas pathway and the LPS recognition pathways occur in vivo (68). Bannerman and associates showed that the key intracellular docking protein which mediates Fas-dependent cellular activation, FADD, negatively regulates LPS-dependent NF-κB activation (69). Expression of a dominant-negative FADD construct blocked NF-κB activation by LPS, and the absence of FADD was associated with increased NF-κB activation as well as increased cytokine production. Ma and associates expanded these findings when they found that Fas-deficient mice had reduced joint inflammation in a model of collagen-induced arthritis, despite having more IL-1β in their joints (70). These studies showed that FADD regulates signaling through TLR4 via binding to MyD88, a proximal signaling molecule common to both IL-1R and TLR4 intracellular pathways. The current paradigm is that when Fas is clustered and FADD is bound to the intracellular tail of Fas, MyD88 is active and signaling through IL-1R and TLR4 is enhanced (Figure 3) (71). In contrast, when Fas is blocked, or inactive as in lpr mice, FADD is more likely to be bound to MyD88, reducing IL-1R– and TLR4-dependent signaling. This model is consistent with our prior observations that LPS-dependent intrapulmonary inflammation is reduced in the Fas-defective lpr mice, and that tissue inflammatory responses after inhaled E. coli are reduced in lpr mice (65, 68).

Figure 3.
Interactions between the Fas-dependent apoptosis pathway and the TLR4 pathway that mediates cellular activation in response to bacterial lipopolysaccharide. FADD, Fas-associated death domain protein. The FADD protein shuttles back and forth between the ...

SHOULD APOPTOSIS BE INHIBITED IN THE LUNGS?

The hypothesis that apoptosis pathways should be inhibited in the lungs of patients with ALI had not been tested rigorously, but several experimental clues make this approach attractive. An important concept is that the role of apoptosis in the pathogenesis of lung disease is likely to depend on the specific cells that are becoming apoptotic. For example, apoptosis of neutrophils may benefit the host by helping the resolution of inflammation, but apoptosis of epithelial cells may lead to disruption of the epithelial barrier and contribute to alveolar flooding. Thus, it may be important to develop cell-specific anti-apoptotic strategies, rather than strategies aimed at blocking apoptosis of all types of cells within the lungs.

We have found that mechanical ventilation and LPS have synergistic effects on the release of sFasL in the lungs of ventilated mice, which may promote apoptosis in the lungs of ventilated mice when bacterial LPS reaches the distal airspaces (unpublished observations). Blockade of caspase activation with ZVAD protected mice from death after systemic LPS administration (59). The studies of Imai and colleagues suggest that inhibiting apoptosis in the systemic circulation could prevent secondary apoptosis to renal tubular epithelial cells and concomitant acute renal insufficiency (58). This observation links lung injury with injury to distant organs, consistent with the lungs as a driver of the multiple organ failure syndrome, and raises hope that inhibitors of apoptosis will be useful in preventing localized injury in the lungs, as well as multiple organ failure. More experimental information is needed to identify the rate-limiting steps in the apoptosis pathways that might be inhibited by new drugs, and the consequences of such inhibition on lung repair, in addition to injury. Nevertheless, new strategies to modulate apoptosis in the lungs could be very useful in reducing ALI in humans. If early apoptosis responses in the alveolar walls are mediated by excess concentrations of agonists like sFasL, then blocking apoptosis early after lung injury might be beneficial. However, if apoptosis is important in the later repair phase, it might be worthwhile to allow apoptosis to proceed later in the course of the illness. Additional experimental data in animals and humans will be required to clarify these important possibilities.

Notes

Supported in part by the Medical Research Service of the Department of Veterans Affairs, and by grants HL69852 and HL073996 from the National Institutes of Health.

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

References

1. NIH ARDSNet Group. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301–1308. [PubMed]
2. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004;351:327–336. [PubMed]
3. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319–323. [PubMed]
4. Ware LB, Matthay MA. Acute Respiratory Distress Syndrome. N Engl J Med 2000;342:1334–1349. [PubMed]
5. Fine A, Janssen-Heininger Y, Soultanakis RP, Swisher SG, Uhal BD. Apoptosis in lung pathophysiology. Am J Physiol Lung Cell Mol Physiol 2000;279:L423–L427. [PubMed]
6. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003;15:325–331. [PubMed]
7. Bachofen M, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977;116:589–615. [PubMed]
8. Bachofen A, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;3:35–56. [PubMed]
9. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002;82:569–600. [PubMed]
10. Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis 1990;142:1250–1257. [PubMed]
11. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;163:1376–1383. [PubMed]
12. Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barbancon V, Buchaklian A, Lei M, Long RM, et al. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J 2003;22:2959–2969. [PubMed]
13. Seeger W, Birkemeyer RG, Ermert L, Suttorp N, Bhakdi S, Duncker HR. Staphylococcal α-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest 1990;63:341–349. [PubMed]
14. Walmrath D, Ghofrani HA, Rosseau S, Schutte H, Cramer A, Kaddus W, Grimminger F, Bhakdi S, Seeger W. Endotoxin “priming” potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin. J Exp Med 1994;180:1437–1443. [PMC free article] [PubMed]
15. Dos Santos CC, Slutsky AS. Mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol 2000;89:1645–1655. [PubMed]
16. Plotz FB, Slutsky AS, van Vught AJ, Heijnen CJ. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. Intensive Care Med 2004;30:1865–1872. [PubMed]
17. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001;1:50–58. [PubMed]
18. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9:1441–1447. [PubMed]
19. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001;28:22–28. [PubMed]
20. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997;159:1594–1598. [PubMed]
21. Tornusciolo DRZ, Schmidt RE, Roth KA. Simultaneous detection of TDT-mediated dUTP-biotin Nick End-Labeling (TUNEL)-Positive cells and multiple immunohistochemical markers in single tissue sections. Biotechniques 1995;19:800–805. [PubMed]
22. Strater J, Gunthert AR, Bruderlein S, Moller P. Microwave irradiation of paraffin-embedded tissue sensitizes the TUNEL method for in situ detection of apoptotic cells. Histochemistry 1995;103:157–160. [PubMed]
23. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis: molecules and mechanisms. Adv Exp Med Biol 1999;457:217–236. [PubMed]
24. Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev 1999;13:239–252. [PubMed]
25. Deveraux QL, Schendel SL, Reed JC. Antiapoptotic proteins: the bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin 2001;19:57–74. [PubMed]
26. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 1998;10:552–558. [PubMed]
27. Bannerman DD, Eiting KT, Winn RK, Harlan JM. FLICE-like inhibitory protein (FLIP) protects against apoptosis and suppresses NF-kappaB activation induced by bacterial lipopolysaccharide. Am J Pathol 2004;165:1423–1431. [PubMed]
28. Tschopp J, Thome M, Hofmann K, Meinl E. The fight of viruses against apoptosis. Curr Opin Genet Dev 1998;8:82–87. [PubMed]
29. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem 1997;272:26159–26165. [PubMed]
30. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001;276:1071–1077. [PubMed]
31. Savill JS, Wylie AW, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989;83:865–875. [PMC free article] [PubMed]
32. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol 2001;11:R795–R805. [PubMed]
33. Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung injury: pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997;156:840–845. [PubMed]
34. Matute-Bello G, Liles WC, Radella FR II, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;156:1969–1977. [PubMed]
35. Bardales RH, Xie S-S, Schaefer RF, Hsu S-M. Apoptosis is a major pathway responsible for the resolution of Type II pneumocytes in acute lung injury. Am J Pathol 1996;149:845–852. [PubMed]
36. Fine A, Anderson NL, Rothstein TL, Williams MC, Gochuico BR. Fas expression in pulmonary alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 1997;273:L64–L71. [PubMed]
37. Hamann KJ, Dorscheid DR, Ko FD, Conforti AE, Sperling AI, Rabe KF, White SR. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium. Am J Respir Cell Mol Biol 1998;19:537–542. [PubMed]
38. Gochuico BR, Miranda KM, Hessel EM, De Bie JJ, Van Oosterhout AJ, Cruikshank WW, Fine A. Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation. Am J Physiol 1998;274:L444–L449. [PubMed]
39. Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, Jonas M, Martin TR. Soluble Fas-Ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol 1999;163:2217–2225. [PubMed]
40. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699–703. [PubMed]
41. Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, Matthay MA, Ware LB. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002;161:1783–1796. [PubMed]
42. Buccellato LJ, Tso M, Akinci OI, Chandel NS, Budinger GR. Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells. J Biol Chem 2004;279:6753–6760. [PubMed]
43. Krick S, Eul BG, Hanze J, Savai R, Grimminger F, Seeger W, Rose F. Role of hypoxia-inducible factor-1alpha in hypoxia-induced apoptosis of primary alveolar epithelial type II cells. Am J Respir Cell Mol Biol 2005;32:395–403. [PubMed]
44. Nakamura M, Matute-Bello G, Liles WC, Hayashi S, Kajikawa O, Lin S-M, Frevert CW, Martin TR. Differential response of human lung epithelial cells to Fas-induced apoptosis. Am J Pathol 2004;164:1949–1958. [PubMed]
45. Matute-Bello G, Liles WC, Frevert CW, Nakamura M, Ballman K, Vathanaprida C, Kiener PA, Martin TR. Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2001;281:L328–L335. [PubMed]
46. Matute-Bello G, Winn RK, Jonas M, Chi EY, Martin TR, Liles WC. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation. Am J Pathol 2001;158:153–161. [PubMed]
47. Wang X, Ryter SW, Dai C, Tang ZL, Watkins SC, Yin XM, Song R, Choi AM. Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway. J Biol Chem 2003;278:29184–29191. [PubMed]
48. Lu Q, Xu DZ, Davidson MT, Hasko G, Deitch EA. Hemorrhagic shock induces endothelial cell apoptosis, which is mediated by factors contained in mesenteric lymph. Crit Care Med 2004;32:2464–2470. [PubMed]
49. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y, Hara N. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17:272–278. [PubMed]
50. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13–19. [PMC free article] [PubMed]
51. Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M, Maeyama T, Hara N. TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 2002;168:6470–6478. [PubMed]
52. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, Hara N. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996;154:477–483. [PubMed]
53. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001;54:132–138. [PMC free article] [PubMed]
54. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997;16:91–101. [PubMed]
55. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143–L151. [PubMed]
56. Uhal BD, Joshi I, True AL, Mundle S, Raza A, Pardo A, Selman M. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995;269:L819–L828. [PubMed]
57. Wang R, Ramos C, Joshi I, Zagariya A, Pardo A, Selman M, Uhal BD. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999;277:L1158–L1164. [PubMed]
58. Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer S, Edwards V, Cutz E, Liu M, Keshavjee S, Martin TR, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 2003;289:2104–2112. [PubMed]
59. Kawasaki M, Kuwano K, Hagimoto N, Matsuba T, Kunitake R, Tanaka T, Maeyama T, Hara N. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol 2000;157:597–603. [PubMed]
60. Plotz PH. The autoantibody repertoire: searching for order. Nat Rev Immunol 2003;3:73–78. [PubMed]
61. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317–1330. [PMC free article] [PubMed]
62. Cocca BA, Cline AM, Radic MZ. Blebs and apoptotic bodies are B cell autoantigens. J Immunol 2002;169:159–166. [PubMed]
63. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA, Witztum JL. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004;200:1359–1370. [PMC free article] [PubMed]
64. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F, Weller M, Gulbins E. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000;290:527–530. [PubMed]
65. Matute-Bello G, Frevert CW, Liles WC, Nakamura M, Ruzinski JT, Wong VA, Vathanaprida C, Martin TR. Fas/fas ligand system mediates epithelial injury, but not pulmonary host defenses, in response to inhaled bacteria. Infect Immun 2001;69:5768–5776. [PMC free article] [PubMed]
66. Hagimoto N, Kuwano K, Kawasaki M, Yoshimi M, Kaneko Y, Kunitake R, Maeyama T, Tanaka T, Hara N. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Biol 1999;21:436–445. [PubMed]
67. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PJ, Liles WC. Fas (CD95) induces pro-inflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 2003;170:6209–6216. [PubMed]
68. Matute-Bello G, Winn RK, Martin TR, Liles WC. Sustained LPS-induced lung inflammation in mice is attenuated by functional deficiency of the Fas/Fas ligand system. Clin Diag Lab Immunol 2004;11:358–361. [PMC free article] [PubMed]
69. Bannerman DD, Tupper JC, Kelly JD, Winn RK, Harlan JM. The Fas-associated death domain protein suppresses activation of NF-kappa B by LPS and IL-1 beta. J Clin Invest 2002;109:419–425. [PMC free article] [PubMed]
70. Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, Cole SM, Pope RM. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat Immunol 2004;5:380–387. [PubMed]
71. Duckett CS. Apoptosis and NF-kappa B: the FADD connection. J Clin Invest 2002;109:579–580. [PMC free article] [PubMed]

Articles from Proceedings of the American Thoracic Society are provided here courtesy of American Thoracic Society